EYPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EYPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EyePoint Pharmaceuticals's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for EyePoint Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, EyePoint Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where EyePoint Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of EyePoint Pharmaceuticals is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
EyePoint Pharmaceuticals (NAS:EYPT) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Goran Ando | director | |
Wendy F Dicicco | director | |
Karen L. Zaderej | director | AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615 |
Nancy Lurker | director, officer: President and CEO | PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458 |
David R Guyer | director | ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119 |
David Scott Jones | officer: SVP & Chief Commercial Officer | C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472 |
Dario A. Paggiarino | officer: Chief Medical Officer | 4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121 |
Ye Liu | director | ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041 |
Michael Craig Pine | officer: Chief Corp Dev.&Strat. Officer | C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472 |
Stuart Duty | director | 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021 |
Ew Healthcare Partners, L.p. | 10 percent owner | 21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380 |
Anthony P Adamis | director | 3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036 |
Therapeutics Ocumension | 10 percent owner | 56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041 |
George Elston | officer: Chief Financial Officer | 124 CHATHAM STREET, CHATHAM NJ 07928 |
John B. Landis | director | 1700 KENT AVENUE, WEST LAFAYETTE IN 46906 |
From GuruFocus
By Marketwired • 02-05-2025
By Marketwired • 03-05-2025
By Marketwired • 01-16-2025
By Marketwired • 10-30-2024
By Marketwired • 02-17-2025
By Marketwired • 01-30-2025
By Marketwired • 02-26-2025
By GuruFocus News • 02-15-2025
By GlobeNewswire • 10-28-2024
By Marketwired • 11-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.